Editas, BlueRock combine forces on gene and cell therapy
April 03, 2019 at 10:29 AM EDT
The companies will combine Editas’ CRISPR/Cas9 gene editing technology and BlueRock’s stem cell platform in the hopes of engineering stem cells.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|